Full text is available at the source.
Abstract
Over 400 million individuals worldwide are affected by neurodegenerative disorders and metabolic diseases.
- Metabolic disorders like diabetes mellitus are significant risk factors for neurodegenerative diseases.
- Current therapies for these conditions primarily focus on symptomatic care rather than disease progression.
- Targeting the mechanistic pathways associated with mTOR may offer new treatment strategies.
- Key pathways of interest include mTOR complex 1 (mTORC1), mTOR complex 2 (mTORC2), and AMP activated protein kinase (AMPK).
- Trophic factors, such as erythropoietin (EPO), and programmed cell death pathways may also play a role in treatment development.
- Further research is needed to ensure that mTOR pathway-based treatments can be safely applied in clinical settings.
Simplified